Geode Capital Management’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $196K | Sell |
164,362
-141,749
| -46% | -$169K | ﹤0.01% | 3883 |
|
|
2025
Q1 | $622K | Buy |
306,111
+4,722
| +2% | +$9.59K | ﹤0.01% | 3469 |
|
|
2024
Q4 | $1.81M | Sell |
301,389
-714
| -0.2% | -$4.3K | ﹤0.01% | 3165 |
|
|
2024
Q3 | $2.12M | Sell |
302,103
-6,290
| -2% | -$44K | ﹤0.01% | 3112 |
|
|
2024
Q2 | $1.79M | Buy |
308,393
+65,547
| +27% | +$380K | ﹤0.01% | 3152 |
|
|
2024
Q1 | $1.74M | Buy |
242,846
+53,646
| +28% | +$384K | ﹤0.01% | 3171 |
|
|
2023
Q4 | $931K | Sell |
189,200
-359
| -0.2% | -$1.77K | ﹤0.01% | 3382 |
|
|
2023
Q3 | $1.81M | Buy |
189,559
+11,106
| +6% | +$106K | ﹤0.01% | 3102 |
|
|
2023
Q2 | $2.31M | Buy |
178,453
+3,049
| +2% | +$39.5K | ﹤0.01% | 3063 |
|
|
2023
Q1 | $2.23M | Buy |
+175,404
| New | +$2.23M | ﹤0.01% | 2979 |
|